라미부딘 내성 소아 청소년 만성 B형 간염에서 Entecavir 치료 경험
Experience with Entecavir Therapy for Lamivudine-Resistant Chronic Hepatitis B in Korean Children and Adolescents
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To estimate the viral suppressive effect of entecavir monotherapy in Korean children and adolescents with lamivudine-resistant chronic hepatitis B (CHB). Methods: One milligram of entecavir was administered once daily to 6 patients (4 boys; mean age, 17.5 years; range, 15.10∼24.6 years) with lamivudine-resistant CHB for a mean duration of therapy of 13.4 months (range, 1∼21.1 months). The therapeutic results were compared with 11 patients who received adefovir (0.3 mg/kg/day [maximal dose 10 mg]) for at least 12 months (mean, 33.4 months; range, 12.4∼58.3 months). The serum HBV DNA level and serologic markers were measured every 2 months. Results: The interval to a HBV DNA titer decrement (＞1 log10) was 1.2±0.2 and 4.4±5.2 months (p=0.185) for the entecavir and adefovir groups, respectively. The interval to a HBV DNA titer decrement (＞2 log10) was 2.4±2.3 and 9.2±7.3 months (p=0.025), for the entecavir and adefovir groups, respectively. Conclusion: The therapeutic efficacy of entecavir was favorable in children and adolescents, especially in shortening the interval to a ＞2 log10 decrement in the HBV DNA titer. Long-term follow up is needed to determine the therapeutic efficacy of entecavir for lamivudine-resistant CHB in children and adolescents. (Korean J Pediatr Gastroenterol Nutr 2010; 13: 44∼50)
Abstract
Purpose: To estimate the viral suppressive effect of entecavir monotherapy in Korean children and adolescents with lamivudine-resistant chronic hepatitis B (CHB). Methods: One milligram of entecavir was administered once daily to 6 patients (4 boys; mean age, 17.5 years; range, 15.10∼24.6 years) with lamivudine-resistant CHB for a mean duration of therapy of 13.4 months (range, 1∼21.1 months). The therapeutic results were compared with 11 patients who received adefovir (0.3 mg/kg/day [maximal dose 10 mg]) for at least 12 months (mean, 33.4 months; range, 12.4∼58.3 months). The serum HBV DNA level and serologic markers were measured every 2 months. Results: The interval to a HBV DNA titer decrement (＞1 log10) was 1.2±0.2 and 4.4±5.2 months (p=0.185) for the entecavir and adefovir groups, respectively. The interval to a HBV DNA titer decrement (＞2 log10) was 2.4±2.3 and 9.2±7.3 months (p=0.025), for the entecavir and adefovir groups, respectively. Conclusion: The therapeutic efficacy of entecavir was favorable in children and adolescents, especially in shortening the interval to a ＞2 log10 decrement in the HBV DNA titer. Long-term follow up is needed to determine the therapeutic efficacy of entecavir for lamivudine-resistant CHB in children and adolescents. (Korean J Pediatr Gastroenterol Nutr 2010; 13: 44∼50)
참고문헌 (33)
- Lok AS, "Navigating the maze of hepatitis B treatments", Gastroenterology, 132, pp.1586~1594 (2007)
- Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
- Perrillo RP, "A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B", Hepatology, 33, pp.424~432 (2001)
- Yao FY, "Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection", J Hepatol, 33, pp.301~307 (2000)
- Dienstag JL, "Histological outcome during long-term lamivudine therapy", Gastroenterology, 124, pp.105~117 (2003)
- Leung N, "Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues", Hepatol Int, 2, pp.163~178 (2008)
- Kurbegov AC, "Hepatitis B therapy in children", Expert Rev Gastroenterol Hepatol, 3, pp.39~49 (2009)
- "약제 산정 기준"[URL]
- Lee JM, "Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir", Antivir Ther, 14, pp.705~712 (2009)
- 황수경, "Lamivudine 내성 소아 청소년 만성 B형 간염에서 Adefovir의 치료 효과", 대한소아소화기영양학회지, 11(2), pp.143~149 (2008), 대한소아소화기영양학회
- Locarnini S, "Management of antiviral resistance in patients with chronic hepatitis B", Antivir Ther, 9, pp.679~693 (2004)
- Sokal EM, "The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection", J Clin Pharmacol, 48, pp.512~517 (2008)
- Jonas MM, "Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to 18 years) with chronic hepatitis B", Hepatology, 47, pp.1863~1871 (2008)
- Sherman M, "Entecavir for treatment of lamivudine- refractory, HBeAg-positive chronic hepatitis B", Gastroenterology, 130, pp.2039~2049 (2006)
- Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
- Schiff ER, "Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients", Hepatology, 38, pp.1419~1427 (2003)
- 대한간학회, "2007년 대한간학회 만성 B형간염 치료 가이드라인", ~ (2007)
- Yang H, "Delaney WE 4th. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine- resistant HBV", Antivir Ther, 10, pp.625~633 (2005)
- Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
- Leung NW, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy", Hepatology, 33, pp.1527~1532 (2001)
- Song BC, "Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea", Hepatology, 32, pp.803~806 (2000)
- 박능화, "만성 B형 간질환 환자에서 라미부딘의 치료 효과 및 예측인자", 대한소화기학회지, 42(4) (2003), 대한소화기학회
- Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
- Marcellin P, "Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B", J Hepatol, 43, pp.920~9223 (2005)
- Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
- Choe WH, "Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir", Antivir Ther, 14, pp.985~993 (2009)
- Sherman M, "Entecavir therapy for lamivudine- refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks", Hepatology, 48, pp.99~108 (2008)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Gish RG, "Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B", Gastroenterology, 133, pp.1437~1444 (2007)
- Lange CM, "Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function", Hepatology, 50, pp.2001~2001 (2009)
- Cohen SM, "Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B", J Clin Gastroenterol, 43, pp.1008~1010 (2009)
- Choe BH, "Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better", J Pediatr Gastroenterol Nutr, 44, pp.92~98 (2007)